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Functional vascularization is a prerequisite for cardiac tissue engineering of constructs with physiological
thicknesses. We previously reported the successful preservation of main vascular conduits in isolated thick
acellular porcine cardiac ventricular ECM (pcECM). We now unveil this scaffold’s potential in supporting
human cardiomyocytes and promoting new blood vessel development ex vivo, providing long-term cell support
in the construct bulk. A custom-designed perfusion bioreactor was developed to remodel such vascularization
ex vivo, demonstrating, for the first time, functional angiogenesis in vitro with various stages of vessel matu-
ration supporting up to 1.7 mm thick constructs. A robust methodology was developed to assess the pcECM
maximal cell capacity, which resembled the human heart cell density. Taken together these results demonstrate
feasibility of producing physiological-like constructs such as the thick pcECM suggested here as a prospective
treatment for end-stage heart failure. Methodologies reported herein may also benefit other tissues, offering a
valuable in vitro setting for ‘‘thick-tissue’’ engineering strategies toward large animal in vivo studies.
Introduction
Despite major advancements in the fields of biomate-rials and cell biology, limited success has been reported
in cardiac regeneration following myocardial infarction, re-
gardless of the material type or cell delivery platform used
(i.e., patch or injection based).1–3 The clinical application of
existing solutions is limited by the lack of functional vascu-
larization,4–6 the inability to ensure efficient cell support in
clinically relevant thick tissue constructs7,8 and the avail-
ability of scaffold biomaterials matching the mechanical and
biochemical properties of the myocardium.1,9
Vascularization is particularly important in constructs
exceeding the thickness of 100–150 mm, representing the
diffusion limitation of soft tissues under static culture con-
ditions.1,7,10–14 Moreover, the ultimate thicknesses achieved
under dynamic culture conditions (< 600 mm), are still far
from that of the natural left ventricular wall (*10–15 mm).1
Consequently, however encouraging the data published
to date may be, the lack of a connectable vascular tree
during transplantation has led to a long lag time while an-
giogenesis occurs, speculated to result in minimal cell re-
tention in the heart’s harsh environment. Vascularization is
needed both to support the establishment of ex vivo culti-
vated cell-seeded constructs,1,4–7,15 and to provide a con-
nectable vascular tree that can instantly supply the tissue
upon transplantation. Hence, the development of dynamic
culture methodologies enabling the production of clinically
relevant tissue-engineered constructs with a connectable
vascular network will have clear implications for this field
and is needed to advance this platform toward clinical
application.
1The Laboratory of Cancer Drug Delivery & Mammalian Cell Technology, Faculty of Biotechnology and Food Engineering, Technion–
Israel Institute of Technology, Haifa, Israel.
2School of Materials Science and Engineering, Nanyang Technological University, Singapore.
3Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore.
4Institute of Technical Chemistry, Leibniz University, Hanover, Germany.
*These two authors contributed equally to this article.
ª Udi Sarig et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,
distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
TISSUE ENGINEERING: Part A
Volume 21, Numbers 9 and 10, 2015
DOI: 10.1089/ten.tea.2014.0477
1507
Recently, our group and others described the isolation of
cardiac acellular extracellular matrix (ECM) from rats16,17
and pigs,7,18–23 which was proposed as an ideal scaffolding
biomaterial for cardiac regeneration. The decellularization
of full-thickness porcine cardiac ventricular ECM (pcECM)
is potentially advantageous, over other tissues and species,
as it highly resembles the human ventricular wall in struc-
ture, size, and composition.24,25 In this study we aimed to
strengthen our ability to support such a platform, demon-
strate the potential of this thick pcECM scaffold, and eval-
uate its long-term cell support and the ex vivo promotion of
new blood vessel generation. For these purposes, a unique
bioreactor system was designed and custom built, enabling
the long-term compartmentalized cocultivation of various
stem and progenitor cells within the thick pcECM construct
under dynamic physiological-like conditions. Cocultures of
human umbilical vein endothelial cells (HUVECs) and hu-
man mesenchymal stem cells (hMSCs) were used herein as
a proof-of-concept to demonstrate the inherent vasculature
functionality and its ability to support the ex vivo re-
population of the thick tissue construct’s bulk. Furthermore,
a simple methodology was developed to statically determine
the pcECM cell holding capacity, predicting a maximal cell
density resembling that of native myocardium. Taken to-
gether, our study demonstrates for the first time the possi-
bility of reconstructing a functional vascular tree ex vivo,
which supports compartmentalized recellularization of thick
myocardial-like tissue constructs. Our study suggests an
alternative and important approach to cardiac tissue engi-
neering, which is based on preserving a connectable inher-
ent vascular tree within the biomaterial scaffold that might
facilitate future survival and function of reseeded constructs
upon transplantation.
Materials and Methods
Preparation of pcECM matrices for static
and dynamic culturing
Porcine left ventricular full-thickness slabs (*10–
15 mm) were perfused and decellularized as previously de-
scribed.7 For static cultivation, thick pcECM matrices were
placed on standard culture plates and cut with a sterile 8 mm
punch (unless stated differently). Matrices were transferred
into 96-well plates, epicardial surface facing downwards.
For dynamic cultivation, pcECM matrices were cut using a
scalpel into *25· 75 · 15 mm slabs containing the perfu-
sion entry catheter already sutured in place (24-gauge, 8 cm
long; Biometrix). Ethanol disinfected catheters (20 min in
70% ethanol) were sutured using a sterile suturing thread (5/
0 nonabsorbable thread) to the other side of the lateral an-
terior descending coronary artery for drainage. Large leaks,
if detected, were shunted by additional suturing. Before cell
seeding, matrices of either cultivation method were washed
with ethanol 70% (1 · 30 min, 1· 2 and 1 · 12 h) followed
by at least three washes with phosphate-buffered saline
(PBS; 3· 30 min), immersion in complete culture media for
12 h, and air-drying in a sterile hood for 2 h.
Cell isolation and cultivation
Bone marrow hMSCs were purchased from Lonza and
cultured in humidified incubator at 37C and 5% CO2 using
alpha modified Eagle’s medium (a-MEM; Biological In-
dustries) supplemented with 20% fetal bovine serum, 1%
Pen-Strep, and 0.4% Fungizone. HUVECs stably expres-
sing GFP (HUVEC-GFP) were kindly donated by Prof. Gera
Neufeld (Technion, Faculty of Medicine)26 and cultured on
gelatin-coated plates (0.2% gelatin in PBS, 37C, > 4 h;
Sigma-Aldrich) with M199 culture media supplemented
with 20% fetal calf serum, 1% Pen-Strep, and 0.4% Fun-
gizone (Life Technologies). Basic fibroblast growth factor
(10 ng/mL) was added to plates of both cell types every
other day. Whenever HUVECs and hMSCs were cocultured,
a-MEM was used. Human embryonic stem cell-derived
cardiomyocytes (hESC-CM) were expanded, differentiated,
and statically cultivated on the pcECM following proto-
cols described in Supplementary Methods (SM) section 1.5
(Supplementary Data are available online at www.liebertpub
.com/tea).
Assessment of pcECM cell support
To evaluate the pcECM maximal cell capacity under
static culture conditions, mathematical modeling was em-
ployed as detailed in the SM section 1.2. This model was
based on empirical data and verified by an additional set of
experiments in which the quantity of cell adhesion foci was
artificially changed, for example, through cross-linking of
hyaluronic acid (HA) to the pcECM matrices, to investigate
the model sensitivity. Detailed information about the model
development, various screening experiments for adhesion
site modifications, and the model verification studies is
presented in the SM sections 1.1–1.3.
The static seeding and cultivation of hMSCs on the
pcECM scaffolds for the mathematical modeling were per-
formed according to our previously published procedure
with slight modifications.7 Briefly, pcECM scaffolds (8 mm
in diameter) were immersed in 96-well plates containing a-
MEM complete culture media for 12 h in cell-culture con-
ditions. Before seeding, media was removed and scaffolds
were left to partially dry for 2 h. HMSCs were resuspended
in complete a-MEM, to a final concentration of 1.4 · 104
cells/mL, seeded on the matrices with increasing cell den-
sities (5· 104, 2 · 105, 4 · 105, and 1.5 · 107 cells/cm2 in
quintuplicate per each density), and cultivated for 21 days.
Seeding was performed through pipettation by slowly ad-
ministering the appropriate cell suspension volume (as per
the cell quantities detailed above) onto the center of the
scaffolds. Seeded scaffolds were preincubated in culturing
conditions for 90 min, previously reported by us as the op-
timal seeding time,7 and transferred to new plates for cul-
tivation. Unless mentioned otherwise, each reseeded matrix
was incubated in 2 mL of hMSC complete growth media,
replenished every other day. Similar experiments were also
performed with HUVECs as detailed in the SM section 1.2.
Bioreactor system design and setup
A schematic description of the bioreactor design and
setup used throughout these experiments is presented in
Figure 1. The ‘‘heart’’ of the system is the perfusion
chamber (Fig. 1a-5–c). This custom-built chamber holds the
matrices in place (marked by a red mesh in Fig. 1c) under
sterile culture conditions, and it enables both pulsatile flow
perfusion and future mechanical and electrical stimulation,
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mimicking the heart physiological environment. The glass
cover enables online monitoring and imaging under sterile
culture conditions. The chamber is located within a standard
CO2 incubator (marked by gray-shaded square in Fig. 1a),
maintaining a temperature of 37C throughout the system. A
MasterFlex peristaltic pump (Fig. 1a-2) is used to pump
the culture media from a glass medium reservoir (Fig. 1a-1;
Radnoti LLC) to the perfusion chamber. A silicon tube
oxygenator (Fig. 1a-4; Radnoti LLC) and a no-return check
valve (Fig. 1a-3; Cole Parmer), located between the pump
and the perfusion chamber ensure maintenance of proper
oxygen levels. A second channel for drainage of excess
culture media from the bioreactor (marked by a dashed line)
pumps the media back into the reservoir. A third low-
volume channel (dotted line) is used to bypass the reservoir
when concentration-dependent measurements are taken to
assess cell quantity and metabolic state throughout long-
term experimentation. System installation, cell seeding, and
standard operation procedure are detailed in the SM sections
1.6 and 1.7.
Determining the dynamic cultivation parameters
To determine the optimal seeding time and perfusion flow
rate, acellular pcECM constructs were seeded with hMSCs
(see SM section 1.7), installed in the perfusion chamber
baths, covered with 60 mL of complete MSC culture media,
and incubated for 1.5 or 24 h before starting perfusion, al-
lowing cell attachment. To measure cell viability, 5% Ala-
marBlue (Invitrogen) in complete culture media was
perfused for 24 h (low volume cycle, bypassing the reser-
voir) at 40 or 80 mL/min. Media samples (300mL) were
taken throughout the culture via the sampling port (Fig. 1a-
6), the AlamarBlue fluorescence intensities were measured
(Ex: 530/25 nm, Em: 595/35 nm), and cell numbers were
calculated thereof versus the appropriate calibration curve.
The survival rate determined 24 h postcommencement of
perfusion was estimated by dividing the AlamarBlue de-
termined cell quantities with the initial seeding quantity
(1.4 · 107 cells/construct). In another experiment, we as-
sessed the optimized cultivation parameters (1.5 h seeding
time, 120 mL/construct perfused at up to 40 mL/min and
replenished every other day) in terms of hMSC support for
up to 7 days (SM section 1.7). Constructs were cross sec-
tioned and stained with hematoxylin and eosin (H&E).
Representative images are presented out of a total of three
constructs processed and at least three histological cross
sections per construct.
Compartmentalized recellularization
The optimized dynamic cultivation parameters were fur-
ther assessed in terms of their effect on constructs, which
were precultivated in steady state densities under static
culture conditions. Thus, hMSCs (3 · 105 cells/cm2) were
seeded onto the endocardial surface of 25· 70 · 15 mm
FIG. 1. A custom-designed bioreactor
system. An overview of the system compo-
nents (a), showing a medium reservoir (1),
which supplies culture media through a
peristaltic pump (2), a check valve (3) and
an oxygenator (4) to a perfusion chamber
(5). Two separate lines are responsible for
drainage either back to the reservoir (dashed
line) or using a smaller volume cycle for cell
quantifications (dotted line). Gray shade
represents a standard CO2 incubator. (6, 7)
Represent three-way faucets and sampling
ports. The perfusion chamber (b, c) has two
identical perfusion baths (b-1) for statistical
repetition, which are located on an elevated
base plate through which all tubing con-
nections are passed (b-2). The baths are
drained from the side using the low volume
cycle (b-4, c-3). The thick porcine cardiac
ventricular ECM matrix (marked by a red
mesh in c-1) is fed by a 24-gauge silicon
catheter (b-3) and is held in place by two
holders (b-5). A balloon (c-2) and electrode
(b-6, b-7, and b-8) subsystems will enable
future mechanical and electrical stimulation,
though these devices were not directly
assessed herein. Color images available
online at www.liebertpub.com/tea
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acellular pcECM slabs, statically monocultured for 30 days,
and transferred to the bioreactor system for dynamic cul-
turing for an additional period of 14 days. Cell viability
(AlamarBlue), density and penetration toward the feeding
blood vessels (histology) were assessed. Alternatively,
HUVECs stably expressing GFP were resuspended (10 · 106
cells/mL) in 0.2% gelatin in complete M199 culture media
and seeded through the vascular network. Fourteen days
postseeding live imaging was performed through confocal
microscopy to evaluate the extent of vascular network
coating, followed by histological cross section and staining
with CD31. More detailed information on the experimental
methodology employed can be found in the SM section 1.8.
Dynamic cocultivation of re-endothelialized
acellular pcECM
Long-term coculture of HUVEC-GFPs and MSCs was
studied for 21 days. HUVEC-GFPs were seeded into the
inherent vasculature of acellular pcECM slabs as we pre-
viously published7,27 with slight modifications, detailed
in the SM section 1.7 and Supplementary Figure S1. Re-
endothelialized matrices (n= 3) were mounted onto the
perfusion chamber and incubated for 1.5 h before starting
perfusion (up to 40 mL/min) with complete M199 media,
which was replenished every other day. For coculturing with
hMSC, the culture media was gradually replaced, during the
first week, with complete a-MEM. One week after re-
endothelialization (t= 8 days), prestained hMSCs (red, Claret-
CellVue; Sigma-Aldrich) were seeded onto the same matrix
by injection as detailed in the SM section 1.8. Seven days
after MSCs were included in the coculture (t= 15 days), hu-
man recombinant vascular endothelial growth factor (VEGF;
Sigma-Aldrich) was added (3 ng/mL) and replenished every
other day for an additional week. Online monitoring was
conducted throughout these experiments, to assess cell vi-
ability, metabolism, process cytotoxicity, and maintenance
of physiological pH. Cell viability was determined using
dynamic AlamarBlue measurements on days 1, 6, 10, 15 and
21. Measurements of glucose (Freestyle; Abbott Labora-
tories) and lactate (Lactate scout; EKF Diagnostics) were
performed throughout the study. Cytotoxicity was evaluated
in culture media 24 and 48 h after media replacement
by measuring the activity of lactate dehydrogenase (LDH)
using an LDH cytotoxicity detection kit (Roche), according
to the manufacturer’s instructions. LDH measurements
represent the excess measured quantity after blank substi-
tution (supplemented fresh culture media not exposed to
cells kept for the same time duration within the same
culture conditions). Background absorbance was elimi-
nated by subtracting reads at 620 nm from the actual reads
at 492 nm. Media pH was measured throughout the pro-
cess using a standard narrow-electrode pH meter (Seven
Easy; Mettler Toledo) and maintained at physiological
levels (7.2–7.4, data not shown) by changing the incuba-
tor’s CO2 concentration.
HUVEC-GFPs were live-imaged within the vascular
network through the perfusion chamber glass cover on days
3, 10, and 21 using Olympus SZX16 (Olympus Corporation)
binocular fluorescent microscope equipped with 0.8 · dry
macro-lens with numerical aperture of 0.3 and a working
distance of 81 mm. Exposure times were coordinated with
those previously determined for blank matrices (before
seeding, data not shown). On day 21 the matrices were re-
moved from the bioreactor and subjected to fluorescent
histological cross-section analyses (see SM section 1.8)
imaged with LSM700 (Carl Zeiss).
Statistical analysis
A pilot screening experiment (n = 6 biological replica per
treatment group, Supplementary Fig. S2) was used to verify
results’ normal distribution and estimate sample size re-
quired based on 70% of measured effect size given con-
ventional a= 0.05 and minimal power of 80%. Outliers were
excluded based on the Mahalanobis D2 method. Border zone
cases were evaluated by the ‘‘Jacknife’’ criteria as well. For
all experiments matrices were randomly allocated for each
group. Unless otherwise specified, results are expressed as
the mean – standard deviation of either five or three bio-
logical repetitions per each experimental group in static
(n = 5) and dynamic (n = 3) studies. Statistical significance in
the differences of the means at individual time point ex-
periments was evaluated by one-way analyses of variance
(ANOVA) and Tukey’s HSD test for multiple comparisons.
Two-way ANOVA with Tukey’s HSD post hoc correction
for interaction and a-level adjustment for multiple com-
parisons was used to test the statistical significance of dif-
ferences among groups through time. Particular contrast
tests on individual treatment effect versus control based on
least square mean estimates per group were performed to
calculate the p-value. In all comparisons, p< 0.05 was
considered significant. Statistical analyses were done using
JMP 6.0 statistical software (SAS).
Results
Assessment of pcECM cell support and capacity
The specific binding of the collagen-binding peptides
(CBPs) to the decellularized thick pcECM was similar to
that observed with commercial collagen (Supplementary
Fig. S3) thereby validating the pcECM structural integrity
and suggesting that it may provide functional support for
reseeded cells. Treating the pcECM with HA was shown to
be more effective in increasing cell attachment and prolif-
eration than treatments with RGD (Arg-Gly-Asp) containing
collagen-binding peptides, cross-linking, nitrocellulose or
sulfated glycosaminoglycans (GAGs, see SM section 1.1,
Supplementary Results and Supplementary Fig. S2).
To measure the scaffold’s cell-holding capacity, increas-
ing densities of hMSCs (n = 5 per seeding density) were
seeded on untreated and HA-treated decellularized scaf-
folds, cultured under static conditions for 24 h, and analyzed
by AlamarBlue, as detailed in the SM sections 1.2 and 1.3.
The cell-loading capacity of HA-treated scaffolds (4.0 · 105
cells/cm2) was significantly higher ( p < 0.0001) than that of
the untreated scaffolds (2.7 · 105 cells/cm2) (Fig. 2a), and
demonstrated high correlation (R2 > 0.96) between the
modeled and empirically measured cell attachments (Fig.
2b). To characterize the effect of cell attachment on the
proliferation and cell growth profile, hMSCs were seeded on
untreated and HA-treated scaffolds in two densities, one
below the maximal density of untreated scaffolds (Fig. 2c)
and one above the maximal density of HA-treated scaffolds
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(Fig. 2d), and cultured for 21 days. While no significant
difference was observed between the treated matrices and
pcECM control at the low seeding density, the HA-treated
scaffolds of the high seeding density, supported cell growth
in significantly higher densities ( p < 0.05) throughout most
of the culturing period (14 days), finally approaching den-
sities similar to those measured on the untreated scaffolds
(1.8 – 0.3 · 105 cells/cm2) after 21 days.
To assess the effect of the medium volume on the final
density of the cultivated cells, hMSCs seeded on untreated
scaffolds were cultured for 21 days in either 2 or 10 mL of
excess culture media, showing higher final densities
(3.1– 0.8· 105 cells/cm2, Fig. 2e) when excess volume was
used corresponding to the predicted maximal cell capacity of
the pcECM. Histological examination performed 21 days
postseeding revealed that the cells were only able to penetrate
100mm deep into the pcECM (Fig. 2f and Supplementary Fig.
S4). However, their volumetric density—estimated by di-
viding the surface density with cellular penetration depth of
0.01 cm/100 mm—was high (*2.7 · 107 cells/cm3).
We also applied the same model for a different cell type,
HUVECs, as an additional verification of the model sensi-
tivity, revealing a pcECM maximal loading capacity for
endothelial cells at a density of 5.4 · 104 cells/cm2 (Sup-
plementary Fig. S5a, b). The loading capacity for HUVECs
was calculated to be fivefold less than that measured for
hMSCs on the same scaffolds. This difference can be at-
tributed to different penetration depths as the HUVEC ap-
peared to remain at a monolayer coating of the pcECM
surface rather than penetrate inside and remodel it (Sup-
plementary Fig. S5c). These values for endothelial cells are
also similar to the cell density of native porcine tissue
coronary artery as evaluated through image analyses of
confocal scans taken from within a freshly harvested porcine
coronary artery (5.0 – 0.7 · 104 cells/cm2, Supplementary
Fig. S5d).
Proving feasibility for pcECM support of cardiac cells
The relevancy of pcECM to cardiac tissue engineering
was demonstrated by its support of hESC-CM (SM section
1.5) forming synchronously beating constructs just 3 days
postseeding (Supplementary Movie SM1). Beating lasted
for at least 3 more weeks during which time, histological
cross sections revealed the presence of the hESC-CM, which
were positively stained for Troponin I, serving as a marker
of the cardiac muscle contraction machinery (Supple-
mentary Fig. S6). In terms of maximal penetration depth,
FIG. 2. Assessment of the pcECM scaf-
folds’ maximal cell capacity. Mathematical
modeling of empirical data sets (a) and a
goodness of fit between predicted and mea-
sured values (b) for hyaluronic acid (HA)
treated (diamonds) and nontreated (circles)
pcECM matrices showing the attachment
density as a function of initial seeding den-
sity. The cell loading capacity of HA-treated
scaffolds (4.0 · 105 cells/cm2) was signifi-
cantly higher ( p< 0.0001) than that of the
nontreated pcECM matrices (2.7 · 105 cells/
cm2). Cell density changes as a function of
time for low (c) and high (d) seeding den-
sities (5 · 104 and 1.5 · 107 cells/cm2, re-
spectively). The effect of medium volume
on cell density is shown in (e). Hematoxylin
and eosin (H&E) staining of representative
histological cross sections of reseeded
pcECM constructs that were cultivated for
21 days, under static culture conditions (f).
For each experimental group and density
there are five biological replicas (n = 5). In-
sets in (c, e) show the least square means
computed by two-way analyses of variance
(ANOVA). * Denotes significantly different
results p < 0.05. Scale bar: (f), 100 mm.
pcECM, porcine cardiac ventricular extra-
cellular matrix. Color images available
online at www.liebertpub.com/tea
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hESC-CMs were localized in the initial 100mm distance
from the surface, similar to what was observed with hMSC
under identical static culture conditions.
Compartmentalized recellularization
A custom-made perfusion bioreactor was designed and
used (Fig. 3a) to study the ability of decellularized pcECM
(Fig. 3b) to support compartmentalization of cell growth
under dynamic culture conditions (Fig. 3). Simultaneous
perfusion of two recellularized thick pcECM scaffolds re-
vealed fully perfused constructs after 48 h that had regained
their full dimensions (Fig. 3c, d). Incubating bulk reseeded
hMSCs for one and a half hours, before perfusion, yielded
significantly higher ( p < 0.05) retention of cell densities
(average of 92%– 10% of the seeded cell quantity) com-
pared to cells that were allowed to attach for 24 h, as de-
termined following a day of perfusion at two physiologically
relevant flow rates (40 and 80 mL/min, Fig. 3f). Utilizing an
attachment time of 1.5 h followed by 7 days of perfusion at
40 mL/min (to decrease possible shear damages), resulted in
hMSC penetration of up to 400mm deep into the pcECM
bulk (Fig. 3e, evidenced by cross-sectional H&E staining).
Elongated cell nuclei aligned along the pcECM fibers sug-
gest that cells were not only physically entrapped within the
scaffold but also attached and anchored to the pcECM in a
more natural way.
A second set of experiments (n= 4) was performed to
evaluate the long-term cell support ability of the dynamic
culture system. HMSCs were statically precultured on the
patch endocardial surface for 30 days, during which cell
density steady states were reached (as modeled in Fig. 2 and
imaged through live confocal in Fig. 3j). The subsequent
dynamic cultivation for 14 days led to a significant increase
( p < 0.001) in cell proliferation of almost fourfold compared
to the steady state value achieved under static conditions
(Fig. 3g). Concomitantly, cell penetration toward the feed-
ing blood vessels increased up to 13-fold compared to
statically cultivated cells (Figs. 2f and 3h, respectively).
Immunofluorescent staining for CD44 (green, counter-
stained with DAPI—blue, Fig. 3i) identified the reseeded
cells attached through their HA receptor to the ECM fibers
(red, autofluorescence).
In another set of experiments, the applicability of this
system to support the re-endothelialization of the pcECM
vascular conduits was demonstrated. HUVECs stably ex-
pressing GFP appeared to form a ‘‘cobble stone-like’’ mor-
phology, as assessed through confocal live imaging (Fig. 3k,
13 days postseeding and dynamic cultivation), achieving a
monolayer coating of the vascular network lumen (Fig. 3l).
Further immunofluorescent staining with CD31 performed on
cross sections of dynamically re-endothelialized constructs
confirmed the endothelial identity of the GFP-expressing
cells and their retention as a monolayer without deviation to
other compartments within the pcECM scaffold.
Ex vivo assembly and functionality of the ECM
vascular network
The assembly and functionality of the vascular network
were assessed using hMSCs and GFP-expressing HUVECs
reseeded within different compartments of the pcECM (bulk
injections and vasculature perfusion, respectively) and co-
cultured under dynamic conditions for 21 days. Online
monitoring using indirect cellular viability and metabolism-
based assays revealed cell proliferation that was correlated
to both increasing quantities of lactate production and to a
parallel decrease in free glucose within the circulating cul-
ture media (Fig. 4a, b, respectively). The addition of VEGF
on day 14 substantially induced cell proliferation, which, a
week later, reached a density of 3.0 · 107 ( – 11%) cells per
scaffold (Fig. 4a). Fluctuations in the measured concentra-
tions from a baseline value to lower (glucose consumption)
and higher (lactate production) levels are the natural result
of culture media replenishing; however, the amplitudes of
these fluctuations correspond to cell metabolism. The mea-
sured LDH levels were indicative of cell death in the early
stages of cell seeding, revealing residual cell death in the
matrix measured 3 days after HUVEC seeding and 2 days
(t = 9 – 1) after the hMSCs were added to the coculture. LDH
levels stabilized with time to baseline levels, suggesting
biocompatibility of the system that does not lead to any
significant cytotoxic effect. The lactate levels measured
exhibited physiological levels (2–8 mM, as per the lactate
meter manufacturer instructions) throughout the entire ex-
perimental timeline.
The presence and organization of HUVEC-GFPs (t= 3
and 21 days) was also monitored online by fluorescent mi-
croscopy (Fig. 4c–e). Endothelial cells demonstrated
sprouting of new capillary-like vessels either through pre-
existing pathways (Fig. 4e) or through the de novo ex vivo
angiogenic sprouting (Fig. 5d). Confocal imaging of cross
sections revealed that cocultured cells were able to reach an
overall thickness of 1.7 mm (Fig. 5a). New blood vessels
sprouted in areas containing high hMSC concentrations on
the outer walls of preexisting blood vessels (indicted by
rectangles Fig. 5a). The nascent blood vessel-like structures
were observed as an ‘‘eruption’’ of endothelial cells (green)
accompanied by hMSCs (red, Fig. 5c, d).
Discussion
Functional vascular supply is one of the most crucial
impediments determining the post-transplantational fate of
recellularized myocardial tissue constructs. Several strate-
gies were suggested to circumvent these limitations. The use
of cocultures incorporating endothelial and pericyte-like
cells, with or without parenchymal model cells, was shown
to improve the prospects of statically cultivated constructs
by enhancing vessel sprouting and connectivity to the host
tissue, post-transplantation.11–14 In another approach, dy-
namic cultivation in vitro of nonvascularized constructs,
using forced medium perfusion, was shown to increase cel-
lular penetration and survival beyond diffusion limitations up
to *600mm from the surface.28–30 This value probably
represents the upper bound of this approach, due to a tradeoff
between insufficient supply of too-low perfusion pressures
and excessive shear stress jeopardizing cell viabilities when
too-high pressures are employed. In both these strategies, the
key hurdle to achieving ultimate human applicable sized
grafts is the long lag-time required for functional angio-
genesis to occur (*2–3 weeks postimplantation).
In recent years it is becoming clearer that ‘‘functional
vascularization’’ is probably required to push the envelope of
current tissue engineering technologies into cellularization of
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thicker and physiologically more relevant constructs. This
is particularly true when the implantation site is ischemic,
for example, the infarcted heart. In this context, we define
herein the concept of ‘‘functional vascularization’’ as the
formation of a connectable branched vascular network
within the construct that can be used to instantly supply the
construct upon implantation. One approach to achieving
such vascularization involves preimplantation of biomate-
rials either on the omentum15 or around femoral arterio-
venous loops employed as cardiac surgical flaps31,32 with
FIG. 3. Compartmentalized dynamic recellularization using monocultures of human mesenchymal stem cells (hMSCs) and
human umbilical vein endothelial cells (HUVECs). A functioning perfusion chamber can be trans-located from the CO2 incubator
into a biological cabinet where sterile handling is available (a). Using this system, decellularized thick pcECM scaffolds (b) regain
full thickness appearance after 48 h of perfusion, as viewed from top or side (c, d, respectively). H&E staining 7 days postseeding (e).
Cell survival when cultivated under various physiological flow rates, using different seeding times (1.5 or 24 h), determined after 24 h
of perfusion (f). * Denotes significantly different results p<0.05. Transferring of statically cultivated thick constructs (t=30 days,
marked with an arrow) to further cultivation in the dynamic system exhibits a significant (p<0.05) increase in cell quantities (g).
Dashed red line represents the 95% confidence interval of the mean. H&E staining of histological cross-sections, 7 days postdynamic
cultivation of hMSCs seeded through the bulk of the pcECM by injection—fibers are shown in red and cell nuclei in blue (h).
Specific antibody staining for CD44 suggests that the hMSCs are anchored to the pcECM through their HA receptors (i). Live
confocal imaging (hMSCs stained with Hoechst) of the endocardial surface after 21 days of static culture reveals densely populated
surfaces in accordance with the mathematical model prediction of steady state densities (j). Re-endothelialization of the vascular
network within the pcECM is demonstrated using a monoculture of HUVEC-GFPs (green) forming 14 days postseeding and
perfusion, a monolayer coating in a cobble stone-like formation (k). Cross-section staining of the GFP expressing cells (green) with
CD31 (red) demonstrated endothelium formation within the lumen of the blood vessel (l). In all experiments, results represent three
biological repetitions (n=3). Scale bars: (e), (h), (j–l), 100mm; (i), 50mm. Color images available online at www.liebertpub.com/tea
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the aim of using the body as the ultimate supportive bio-
reactor. Another approach suggests the ex vivo construction
of vascular beds from very basic building blocks using
isolated native artery and vein embedded in a thymosin
beta4-hydrogel.4 The functionality of this vascular bed and
the ultimate cellularized tissue thicknesses that can be ob-
tained by this approach are still not sufficiently understood.
Though producing valuable insights, both the above ap-
proaches are associated with donor site morbidity, further
complicating clinical applicability.
An alternative approach to attaining functional construct
vascularization may be premised on the use of preserved
vascular conduits within decellularized myocardial ECM.
Indeed, several groups including our own have recently
reported on procedures for isolating myocardial ECM of
porcine origin7,18–23—indicating the growing interest in this
relatively new biomaterial. As the porcine heart is anatom-
ically similar to the human heart,7,23–25 this thick composite
bio-material holds high potential for myocardial replace-
ment therapies.1,8,18,23 These scaffolds were also suggested
to be advantageous over other materials given that they
contain the ultra-structural mesh of inter-species conserved
proteins and bioactive molecules that comprise natural
myocardial ECM, which may better support expected re-
generation and circumvent issues of immunogenicity. A
distinction, however, should be made between whole heart
porcine ECM templates8,18,21 and downscaled ventricular
full-wall ECM scaffolds.7,23 Currently, the recellularization
of big whole heart templates presents significant technolog-
ical hurdles due to the complexity of cell types and quantities
required,8 their effective delivery and organization within
organ distinct parenchymal localities,33 and the development
of relevant dynamic culturing technologies. The latter should
enable continued viability and sterility for the relatively long
time durations required for cell proliferation, organization,
and maturation within their respective compartments. In this
context the downscaling from whole heart templates to thick
decellularized full wall ventricular slabs7,23 may be advan-
tageous, pending sufficient preservation of the ventricular
wall major ECM constituents and a supportive blood vessel
infrastructure. Thus, downscaling will likely substantially
reduce the complexity of cell quantities, types and delivery
FIG. 4. Dynamic coculturing and revascularization of thick pcECM scaffolds. Online monitoring of cell culture condi-
tions throughout the dynamic long-term cocultivation of HUVEC-GFPs and hMSCs (a, b). Total cell quantity and cell
lactate dehydrogenase (LDH)-cytotoxicity evaluation (circles and squares, respectively) are presented as a function of time
(a). Glucose consumption and lactate production (circles and squares, respectively) as measures of cell metabolism are
presented as a function of time (b). Reduction in glucose and increase in the level of lactate are attributed to cell metabolism
whereas an increase in glucose and reduction in lactate levels are the consequences of culture medium changes zeroing the
measurements to their baseline level. Vertical error bars represent standard error of the mean. Horizontal error bars represent
standard deviation in time. Fluorescent monitoring of HUVEC-GFPs throughout the coculture dynamic experiment,
showing live imaging of most of the large pcECM installed, including the main blood vessels at t = 3 (c), and (d) 21 days. (e)
A zoom-in view on the white rectangle appearing in (d). Scale bars: 2 mm. In all experiments, results represent three
biological repetitions (n = 3). Color images available online at www.liebertpub.com/tea
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methods required for experimentation, and enable—under
careful bioreactor design (Fig. 1)—more feasible long-term
experimentation with compartmentalized recellularization in
a noncontaminated environment.
In this study we aimed to reconstruct an inherent func-
tional vascular bed that supports recellularization of physi-
ologically relevant thicknesses using a completely in vitro
setting (i.e., independent of donor organs or tissues). We
hypothesized that the preserved vascular network within the
pcECM scaffold studied herein can provide the basis for the
ex vivo construction of thick (i.e., > 600 mm) recellularized
myocardial-like tissue constructs, in a compartmentalized
manner. For these purposes thick pcECM was evaluated
herein in terms of its cell support capacity and functional
vasculature assembly under static and dynamic culture con-
ditions, using a bioreactor system custom-built to provide
physiological mimicking conditions ex vivo. Two cell types
were primarily employed in this study and used as model
cells for endothelial (HUVECs) and pericytic/parenchymal
(MSCs) functions to enable possible self-assembly of more
mature and functional blood vessels within the construct.
The technology developed herein may be readily applicable
to many other ECM-based approaches, regardless of the
ECM tissue origin or parenchymal cell types required for the
engineered construct ultimate function, so long as the in-
herent vascular network is preserved within the material.
The cell supporting capacity of pcECM scaffolds was
initially evaluated under static culture conditions. We de-
veloped a simple methodology to mathematically model the
maximal cell holding capacity of the pcECM (Fig. 2). The
predicted (model) and measured (empirical data) maximal
pcECM volumetric cell holding capacity (2.7 · 107 cells/
cm3) closely approximated the actual density of CM in the
adult human heart (2 · 107 CM/cm3).34 Our suggested model
was further validated in three ways. First, by artificially
increasing the quantity of cell adhesion sites, a corre-
sponding increase in the model’s prediction of maximal cell
capacity was revealed. Second, long-term cultivation ex-
hibited convergence of cell densities even when the initial
seeding densities were far below and above the model’s
estimated predictions. Third, when a different cell type was
used (HUVECS) different values were obtained suggesting
sensitivity of the model to specific cell–scaffold interactions
(Supplementary Fig. S5). Interestingly, the values measured
and computed for HUVECs also corresponded to the mea-
sured endothelial cell density in the luminal surface of the
porcine coronary artery (SM section 1.4 and Supplementary
Fig. S5d) and corresponded to that reported for completely
biological engineered vascular grafts using human endo-
thelial cells.35
Several other mathematical models have been suggested in
recent years to enable the characterization of cell quantities
within scaffold biomaterials under both static36–40 and dy-
namic29,41–45 culture conditions. In general, the models based
on static cultivation are usually too complex to be routinely
used for biological screening or biomaterial characterizing,
while the dynamic models are usually multifactorial, limiting
applicability when simple static conditions are at hand. To
the best of our knowledge, this is the first time such a simple
and easily applicable model is suggested for these purposes
and could probably be easily applied to any particular cell
and biomaterial scaffold combination within 24–96 h of
seeding. Furthermore, our findings indicate that maximal cell
capacity is an important cell–scaffold characteristic, which
may predict the scaffold’s long-term cell support ability gi-
ven a set of defined culture conditions. Nevertheless, this
FIG. 5. In vitro functional angiogenesis. A
cross-sectional overview of a small arteriole
and its surrounding tissue 21 days post co-
culture dynamic cultivation (a, 2 · 2 mm
field of view). Sprouting of new vessel-like
pathways, in various stages of maturation, is
subjected to interplay between the sprouting
HUVEC-GFPs (green) and hMSCs (Cell-
Vue Claret, red) at the periphery of the
supply arterioles. (b, c) Represent higher
magnification of the rectangles marked in
(a; yellow and red, respectively). These
panels show different stages of cell sprout-
ing. At the initial stages of sprouting,
hMSCs seem to concentrate around the base
of the newly formed vessel (c), followed by
eruption of an endothelial cell front accom-
panied by fewer hMSCs as also demon-
strated in (b, d). Scale bars: 200 mm. In all
experiments, results represent three bio-
logical repetitions (n = 3). Color images
available online at www.liebertpub
.com/tea
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may be limited in applicability for scaffolds in which deg-
radation is fast. For example, rapidly degrading scaffolds
(e.g., PLGA) may modify their available surface area and
diffusion patterns through time, affecting the cell maximal
holding capacity of the scaffold. In our hands, though, the
pcECM was only mildly remodeled during the experimental
timeline and therefore our findings remained valid for at least
2–3 weeks—a period of time, which is usually applicable for
most of the practical laboratory tests.
As the pcECM scaffold was isolated using decellular-
ization, some damage may be expected, which usually
comprises both GAG washout and the disruption of the
collagenous structural network.46,47 GAG and collagen-
binding sites were previously reported to independently in-
fluence cell adhesion and proliferation within the heart.48
Therefore, we performed screening experiments in which
cell adhesion sites were artificially introduced into the
pcECM, with the aim of identifying the optimal cell adhe-
sion site modification for model verification. These screen-
ing experiments may also indicate the extent of the damage
that might have been caused by the decellularization, given
that the addition of a missing component would be expected
to result in increased cell attachment and proliferation on the
pcECM. Thus, CBPs, GAG (representatives of both sulfated
and nonsulfated groups), nitrocellulose, and simple cross-
linking were evaluated with various combinations (Supple-
mentary Figs S2 and S3). The functional collagen binding
with specific CBP-RGD residues suggested the preservation
of collagen-binding sites during our decellularization pro-
cedure. Furthermore, the fact that no significant difference
was observed between pcECM treated with CBP containing
RGD moieties compared to nontreated matrices in terms of
cell attachment and proliferation suggests that structural
binding motifs are not lacking within the pcECM. In con-
trast, addition of glycoside moieties (nitrocellulose, sulfated
and nonsulfated GAG) were shown to be much better cell
adhesion modifiers (with the best effect measured for HA
addition, p = 1.8 · 10- 6) postdecellularization. Interestingly,
though initially differing, the final cell density (t = 21) was
similar in both HA-conjugated and nontreated pcECM ma-
trices, suggesting that the effect of GAG conjugation is
limited. This transient effect might be attributable to the
synthesis and secretion of GAG by the reseeded cells
themselves,49 altering the pcECM composition with time.
To better visualize the cells within the reseeded pcECM
scaffolds, histological sections were performed, revealing a
relatively high cell density within a narrow depth of pene-
tration (*100mm). This limited penetration depth is similar
to the known ‘‘soft-tissue’’ diffusion limitation that is as-
sociated with heart and muscle regeneration,1,4–6 further
suggesting that the pcECM scaffolds can be recellularized to
a physiologically similar density. Interestingly, the cultiva-
tion of cardiac parenchymal cells (i.e., CM) resulted in the
formation of synchronously beating constructs starting from
3 days postseeding (Supplementary Movie SM1 and Sup-
plementary Data). In fact, the CMs were well supported by
the pcECM within a similar penetration depth as that mea-
sured for hMSCs (Supplementary Fig. S6).
We therefore hypothesized that nutrient and medium
volume may be a limiting factor in cell proliferation within
these initial 100mm of penetration depth. Increasing the
volume of culture media per construct by fivefold enabled us
to reach the predicted theoretical values, for hMSCs used
here as model cells, after 21 days of culture. However, no
further improvements were observed, even when using larger
medium volumes (data not shown), pointing to the limitation
associated with static culture conditions. This observation
led us to the development of the dynamic cultivation plat-
form for thick pcECM constructs presented herein.
To enable long-term support of cellular proliferation we
designed a new perfusion bioreactor system, encompassing
physiological mimicking pulsatile perfusion capabilities
along with room for future electro-mechanical stimulation
subsystems. We hypothesized that by using the perfusion
features of this bioreactor, we can provide cell support
within a relatively thick and viable construct, which relies
on the pcECM’s inherently preserved blood vessel infra-
structure. To test its applicability, we initially conducted a
series of short-term optimizations to ensure proper physio-
logical flow rates and sufficient seeding times were used.
These experiments revealed that when hMSCs were injected
into the bulk cavities of the thick pcECM scaffold and al-
lowed to adhere for 90 min, high cell viabilities are achieved
over 48 h periods, with reseeded and perfused constructs
swelling back to human equivalent left ventricular dimen-
sions. The cultivation of such constructs for 7 days revealed
cell clusters aligned to the ECM fibers within the scaffold
bulk, with a depth of up to four times greater than that ob-
served under static culture conditions. Furthermore, the ad-
vantage of this bioreactor system over static tissue culture
was demonstrated by sequential cultivation of statically
precultured constructs that were allowed to reach cell density
steady state, before their dynamic expansion for an addi-
tional period of 14 days. Under dynamic conditions, the
observed increase in cell penetration and viability beyond the
steady state values suggests that reseeded cells have migrated
toward the nourishing blood vessels where presumably fresh
oxygen and nutrients are available. The advantage of such an
approach is in providing a biomimetic milieu for functional
cell assembly that may, in turn, lead to CM orientation and
survival, as also recently proposed by Chiu et al.4
Another major hurdle to any future transplantation strat-
egy is achieving a proper vascular re-endothelialization of
decellularized grafts, thus minimizing blood coagulation
and aneurism formation.50 The re-endothelialization is also
a prerequisite to the support of thick tissue-engineered
constructs. As a proof of concept, the isolated thick pcECM
scaffold and its adapted bioreactor system were also studied
in terms of their ability to support such re-endothelialization.
Seeing as both the coculture with MSC51,52 and the admin-
istration of VEGF4,53 were previously reported to be asso-
ciated with blood vessel sprouting and maturation, they were
both used in our experimental setup. Under dynamic cocul-
ture conditions, the blood vessel network of the thick pcECM
constructs became revitalized, exhibiting various levels of
vessel sprouting and maturation. MSCs added to the culture
system demonstrated a pericytic-like support for the endo-
thelial cells as evident by the histological cross-section an-
alyses performed, and further supported by several reports on
the role of MSCs as pericytes in vivo.54,55 The addition of
VEGF to the culture media contributed to a dramatic in-
crease in cell proliferation accompanied with vessel sprout-
ing from various locations both through predetermined paths
within the ECM and through de novo created tracks (Figs. 4
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and 5 and Supplementary Fig. S7). The effect of VEGF
addition to vessel sprouting was also recently reported by the
Radisic group in a hydrogel model utilizing native arteries
and veins as the main supplying vessels.4 Of note is that, in
our hands, the effect of VEGF addition was time dependent
as its addition in premature states (i.e., before MSC seeding)
resulted in insignificant re-endothelialization (data not
shown). This is, to the best of our knowledge, the first time
such a delicate process of vessel sprouting from within large
reseeded acellular conduits (< 1 mm in diameter, *5–6 mm
in length) has been documented in a completely in vitro
environment. Thus, the bioreactor and scaffold setup pre-
sented in our work can also be used for further studies of the
delicate interplay between various cell types related to an-
giogenesis and cardiac restoration therapies.
Finally, the coculture of endothelial cells and MSCs using
this novel perfusion bioreactor system also enabled the
achievement of a relatively thick cell-supportive ECM tissue
construct (*1.7 mm, Fig. 5), which is, to the best of our
knowledge, unprecedented in a completely in vitro system.
This is comparable to the maximal reported thickness
achieved to date using in vivo corporal systems as the op-
timal bioreactor setup.31 Though the bioreactor design also
contains additional means to provide both electrical and
mechanical stimuli for preconditioning to improve cell or-
ganization within the scaffold these were not tested within
the context of this article. Further experimentations are be-
ing conducted to address these issues.
In conclusion, this study presents two major findings/
methodologies: The ex vivo genesis of functional vascula-
ture and the quick characterization of scaffold biomaterials
in terms of their maximal cell capacity and long-term cell
support ability. Both methodologies reported herein were
demonstrated through the use of pcECM thick constructs
and a new custom-developed dynamic cultivation technol-
ogy. We have shown that using such a careful and sys-
tematic approach, the support of physiological-like cell
densities in up to 1.7 mm thick viable constructs is possible
in a completely ex vivo environment. These findings raise
the bar for state-of-the-art myocardial tissue engineering and
reaffirm the potential of thick acellular pcECM as an ex-
citing biomaterial with a clinical potential for regenerative
cardiac medicine. Furthermore, this system offers a unique
platform for in vitro studies of decellularized soft-tissue
ECM-based tissue engineering strategies, such as the
pcECM demonstrated herein. Nevertheless, to achieve
morphologies that better resemble the cardiac native tissue,
the incorporation of parenchymal cells (e.g., CM) into the
dynamically cultivated constructs and the study of addi-
tional mechano-electrical stimulation in the designed bio-
reactor, are required. We expect such experimentation, to
further exploit the potential of the thick pcECM matrix and
bioreactor system reported herein.
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